Directional migration of adult hematopoeitic progenitors to C6 glioma in vitro

Abstract

Abstract. Multiform glioblastoma is the most common primary, highly invasive, malignant tumor of the central nervous system, with an extremely poor prognosis. The median survival of patients following surgical resection, radiation therapy and chemotherapy does not exceed 12-15 months and thus, novel approaches for the treatment of the disease are required. The phenomenon of the directed migration of stem cells in tumor tissue presents a novel approach for the development of technologies that facilitate the targeted delivery of drugs and other therapeutic agents to the tumor foci. Hematopoietic cluster of differentiation (CD)34 + /CD133 + stem cells possess significant reparative potential and are inert with respect to normal neural tissue. The aim of the present study was to investigate the substantiation ability of adult hematopoietic progenitors to the directed migration of glioma cells. A C6 glioma cell line, a culture of hematopoietic CD34 + /CD133 + stem cells and primary cultures of rat astrocytes and fibroblasts were used. The cells were co-cultured for five days. The results revealed the formation of cell shaft hematopoietic stem cells on the perimeter of the culture inserts containing the glioma culture. However, this was not observed in the wells with fibroblast and astrocyte cultures. The results indicated that hematopoietic stem cells exhibit a high potential for the directional migration of C6 glioma cells, which allows them to be considered as a promising cell line for the development of novel anticancer biomedical technologies and increases our understanding with regard to previously unclear aspects of glial tumor carcinogenesis.

Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review)

“…Mammalian and human postnatal stem cells possess pronounced anti-tumor potential, while they are capable of directed migration to and interaction with tumor cells. Previous studies by our group ( 83 , 84 ) and studies by other researchers ( 85 , 86 ) have described this phenomenon using models of gliomas, metastatic melanoma ( 87 ), solid tumors ( 88 ) and CSCs of metastatic tumors ( 89 ). The vector of migration activity for normal tissue-specific stem cells in relation to GBM cells is inversely proportional to the differentiation level of cancer cells and is more pronounced among cells with one histogenetic source in the brain ( 86 ) that allows to target CSCs directly using neural stem cells.…”

“…3A–D . This phenomenon is observed in 40% of C6 glioma cells, 77% of lung cancer cells (А549), 47% of breast adenocarcinoma cells and 64% of human glioblastoma cells ( 83 , 84 ).…”

Vaccination in the immunotherapy of glioblastoma

“…Bryukhovetskiy et al reported that cancer stem cells (CSCs) were very difficult to destroy and could recruit other types of stem cells, and they proteomically identified an interaction between CSCs and hematopoietic stem cells (HSCs). 115,116 An animal model has confirmed this hypothesis, 117 and a clinical trial (NCT01759810) investigating concurrent HSCs, DC vaccines and cytotoxic lymphocytes in the treatment of GBM has been conducted. 58 In addition to cellbased vaccines, other cell-based immunotherapies, such as adoptive cellular therapy (ACT), have shown potential feasibility for clinical application.…”

Novel cellular and post-genomic technologies in the treatment of glioblastoma multiforme (Review)

“…However, experimental data show that the original source of cytokines can be tumor cells themselves (51,52). Having autonomy, they can synthesize their own cytokines.…”